首页> 外文期刊>Frontiers in Pharmacology >HLA-B * 58:01 for Allopurinol-Induced Cutaneous Adverse Drug Reactions: Implication for Clinical Interpretation in Thailand
【24h】

HLA-B * 58:01 for Allopurinol-Induced Cutaneous Adverse Drug Reactions: Implication for Clinical Interpretation in Thailand

机译: HLA-B * 58:01 用于别嘌呤醇诱导的皮肤不良药物反应:在泰国的临床解释意义

获取原文
       

摘要

Background: The aim of this study was to investigate the predisposition to different types of allopurinol-induced cutaneous adverse drug reactions (CADR), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN; SJS-TEN, n = 13), drug reaction with eosinophilia and systemic symptoms (DRESS, n = 10) and Maculopapular eruption (MPE; n = 7), conferred by HLA-B ~(*) 58:01 in a Thai population. Methods: This case-control association study compares 30 patients with allopurinol-induced CADR, allopurinol-tolerant control patients ( n = 100), and a Thai general population ( n = 1095). Patients' human leukocyte antigen type B (HLA-B) alleles were genotyped by using a two-stage sequence-specific oligonucleotide probe system. Results: Of a total 30 patients with CADR due to allopurinol, 29 (96.7%) patients were found to be at least heterozygous for HLA-B ~(*) 58:01 , compared to only 4.0% in allopurinol-tolerant patients ( p < 0.001). Odds ratio (OR) for the association of HLA-B ~(*) 58:01 with allopurinol-induced CADR in this population was 696.0 (95% CI: 74.8–6475.0). The HLA-B ~(*) 58:01 allele was present in all patients with allopurinol-induced SJS-TEN (OR = 579.0, 95%CI: 29.5–11362.7, p < 0.001) and DRESS (OR 430.3, 95%CI: 22.6–8958.9, p < 0.001). Additionally, OR of HLA-B ~(*) 58:01 was highly significant in the allopurinol-induced MPE patients (OR 144.0, 95%CI: 13.9–1497.0, p < 0.001). Conclusion: In this study we confirmed the association between HLAB ~(*) 58:01 and allopurinol-induced SJS-TEN in a Thai population. In addition, we identified an association between HLA-B ~(*) 58:01 and allopurinol-induced DRESS and MPE in this population. Therefore, HLA-B ~(*) 58:01 can be used as a pharmacogenetic marker for allopurinol-induced CADR including SJS-TEN, DRESS and MPE. These results suggest that screening for HLA-B ~(*) 58:01 alleles in patients who will be treated with allopurinol would be clinically helpful in preventing the risk of developing CARD in a Thai patients. Summary Regardless of phenotype, this is the first pharmacogenetic study of allopurinol-induced CADR in patients of Thai ancestry. In this study we confirmed the association between HLA-B ~(*) 58:01 and allopurinol-induced SJS-TEN, DRESS, and MPE in Thai population. Regarding to our findings, the pharmacogenetic interpretation could be generalized to drug hypersensitivity including DRESS, SJS-TEN, and MPE.
机译:背景:这项研究的目的是调查不同类型的别嘌呤醇诱导的皮肤不良药物反应(CADR)的诱因,包括史蒂文斯-约翰逊综合征(SJS),中毒性表皮坏死溶解(TEN; SJS-TEN,n = 13) ,由泰国人群中的HLA-B〜(*)58:01引起的具有嗜酸性粒细胞增多和全身症状(DRESS,n = 10)和斑丘疹(MPE; n = 7)的药物反应。方法:该病例对照协会研究比较了30例别嘌呤醇诱导的CADR患者,耐受别嘌呤醇的对照患者(n = 100)和泰国普通人群(n = 1095)。使用两阶段序列特异性寡核苷酸探针系统对患者的人类白细胞抗原B型(HLA-B)等位基因进行基因分型。结果:在总共30名因别嘌呤醇引起的CADR患者中,发现29名(96.7%)患者的HLA-B〜(*)58:01至少是杂合的,而对别嘌呤醇耐受的患者只有4.0%(p <0.001)。该人群中HLA-B〜(*)58:01与别嘌呤醇诱导的CADR关联的几率(OR)为696.0(95%CI:74.8–6475.0)。 HLA-B〜(*)58:01等位基因存在于所有由别嘌呤醇诱导的SJS-TEN(OR = 579.0,95%CI:29.5-11362.7,p <0.001)和DRESS(OR 430.3,95%CI)中的患者:22.6–8958.9,p <0.001)。此外,HLA-B〜(*)58:01的OR在别嘌呤醇诱导的MPE患者中非常显着(OR 144.0,95%CI:13.9-1497.0,p <0.001)。结论:在这项研究中,我们证实了泰国人群中HLAB〜(*)58:01与别嘌呤醇诱导的SJS-TEN之间的关联。此外,我们在该人群中发现HLA-B〜(*)58:01与别嘌呤醇诱导的DRESS和MPE之间存在关联。因此,HLA-B〜(*)58:01可用作别嘌呤醇诱导的CADR的药物遗传标志,包括SJS-TEN,DRESS和MPE。这些结果表明,在将接受别嘌呤醇治疗的患者中筛查HLA-B〜(*)58:01等位基因在临床上有助于预防泰国患者发生CARD的风险。总结不论表型如何,这都是泰国血统中别嘌呤醇诱导的CADR的首次药物遗传学研究。在这项研究中,我们证实了泰国人群中HLA-B〜(*)58:01与别嘌呤醇诱导的SJS-TEN,DRESS和MPE之间的关联。根据我们的发现,药理遗传学解释可以推广到包括DRESS,SJS-TEN和MPE在内的药物超敏反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号